Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999–2018)

Author:

Camphor Hendrik S1,Viney Kerri2,Polkinghorne Ben3,Pennington Kate4

Affiliation:

1. 1-Research School of Population Health, Australian National University, Canberra, Australia. 2-Communicable Diseases Epidemiology and Surveillance Section, Office of Health Protection, Australian Government Department of Health

2. 1-Research School of Population Health, Australian National University, Canberra, Australia.3-Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.

3. Research School of Population Health, Australian National University, Canberra, Australia.

4. Communicable Diseases Epidemiology and Surveillance Section, Office of Health Protection, Australian Government Department of Health

Abstract

This study describes the epidemiology and treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) cases notified in Australia between 1999 and 2018, and investigates whether current data fields in the national tuberculosis (TB) dataset allow description and measurement of surveillance information pertaining to the diagnosis and clinical management of MDR-TB. In May 2019, de-identified demographic, clinical, laboratory, drug susceptibility, treatment, risk factor and outcome data for all MDR-TB case notifications were extracted from the Australian National Notifiable Disease Surveillance System. The dataset included ten treatment outcome categories, which were aggregated to four categorical outcomes for descriptive and inferential analyses. The majority of cases were overseas-born (91%). Absolute case numbers increased over time; however, the MDR-TB notification rate remained fairly stable during the study period. Treatment success was achieved in nearly two-thirds of cases (62.1%). Whilst timeframes between initial presentation, specimen collection, case notification and treatment commencement were calculated, current data fields in the national dataset precluded measurement and description of other parameters deemed important for MDR-TB surveillance. This study demonstrates that while Australia’s MDR-TB burden is low, cases will continue to occur until TB control improves in countries with which Australia shares cultural and migration links. Australia should continue to support national and regional TB control programmes to sustain progress towards national elimination of TB. This study’s findings support a review of data fields in the national TB dataset with potential expansion or adjustment to improve national data reporting, including the monitoring of evidence-based recommendations for the prevention and management of MDR-TB.

Publisher

Australian Government Department of Health

Subject

General Medicine

Reference34 articles.

1. World Health Organization (WHO). Tuberculosis. [Internet.] Geneva: WHO; 2018. Available from: http://www.who.int/en/news-room/fact-sheets/detail/tuberculosis.

2. Francis JR, Manchikanti P, Blyth CC, Denholm J, Lowbridge C, Coulter C et al. Multidrug-resistant tuberculosis in Australia, 1998–2012. Int J Tuberc Lung Dis. 2018;22(3):294–9.

3. WHO. Global tuberculosis report 2018. Geneva: WHO; 2018. Available from: https://www.who.int/tb/publications/2018/en/.

4. Trauer JM, Cheng AC. Multidrug-resistant tuberculosis in Australia and our region. Med J Aust. 2016;204(7):251–3.

5. WHO. The End TB Strategy. [Internet.] Geneva: WHO; 2014. Available from: http://www.who.int/tb/strategy/en/.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3